Shanghai Microport Medbot (group) Co., Ltd. Class H · HKEX:2252
Shanghai Microport Medbot (group) Co., Ltd. Class H — FY2022 Earnings Presentation
29 slides from Shanghai Microport Medbot (group) Co., Ltd. Class H's earnings presentation, March 2023
Slide 1: 2022 Annual Presentation
2022 Annual Presentation MARCH 2023 Strictly Private and Confidential
Slide 2: Agenda
Agenda Business highlights Commercialization Product pipeline update Financial review Appendix CONFIDENTIAL 1
Slide 3: FY 2022 achievements at a glance
FY 2022 achievements at a glance In 2022, we achieved outstanding pipeline and commercialization progress in five major surgical specialties 4 products won new bids/trial orders in Greater China and US markets, paving the way for robust growth of revenue in FY23E Financial highlights Product Pipelin
Slide 4: Agenda
Agenda Business highlights Commercialization Product pipeline update Financial review Appendix CONFIDENTIAL 3
Slide 5: 1st year of commercialization - Successive orders from reputable hospitals
1st year of commercialization - Successive orders from reputable hospitals 4 products winning bids in 3 surgical specialties with more sales indications from other hospitals Paving the way for robust growth in FY23 revenue winning bids Toumai® 1st Chinese laparoscopic surgical robot to achieve comme
Slide 6: Leading domestic player to conduct large scale surgeon trainings
Leading domestic player to conduct large scale surgeon trainings Training center layout Active deployment of training centers in 2022 Training centers extensively established nationwide, covering most Chinese provinces and major cities, mainly through collaboration with reputable hospitals Over
Slide 7: Integration of 5G technology and surgical robot
Integration of 5G technology and surgical robot Long range 5G technology application in robot assisted tele-surgeries and training > 5,000 km 1st 5G ultra-long-range 5G tele-surgery from 5G long range surgical minimal invasive procedure Gansu Provincial procedure training training center established
Slide 8: Agenda
Agenda Business highlights Commercialization Product pipeline update Financial review Appendix CONFIDENTIAL 7
Slide 9: Comprehensive product offering covering all major and fast-growing surgical specialties
Comprehensive product offering covering all 5 major and fast- growing surgical specialties 12 products covering 5 surgical specialties Development stage Medical Device Surgical Indicated Product Clinical Trial/ Specialty Product Application Classification Design Development Design Validation Clinica
Slide 10: Flagship product – Toumai Laparoscopic Surgical Robot
Flagship product – Toumai® Laparoscopic Surgical Robot 1st Domestic laparoscopic surgical robot 1st Domestic laparoscopic surgical robot Surgical robots orders received received NMPA approval to realize commercial installation Toumai® 1st Generation Multiple generations of Toumai clinical progress 2
Slide 11: Large scale clinical validation of Toumai
Large scale clinical validation of Toumai® LARGE VOLUME clinical validation operations 16 31 Provinces Hospitals to ensure safety and reliability ~700 WIDE COVERAGE clinical procedures across developed completed up to date and lower tier cities Premium quality Safety and reliability confirmed thro
Slide 12: Large scale clinical validation of Toumai (cont'd)
Large scale clinical validation of Toumai® (cont’d) LEADING CAPABILITY HIGH FREQUENCY providing safer, easier and more intense validation with successive operations efficient solutions for difficult and complicated diseases First of its kind completed with a Chinese- Shandong Provincial Hospital Aff
Slide 13: Flagship product – SkyWalker Orthopedic Surgical Robot
Flagship product – SkyWalkerTM Orthopedic Surgical Robot First and only domestic orthopaedic surgical robot with NMPA, FDA and CE approvals Large scale safety and reliability validation surgeries Meizhou Huizhou, Shantou Hollis, U.S. Meizhou People’s Hospital’s First TKA 1st TKA procedure performed
Slide 14: Flagship product – SkyWalker Orthopedic Surgical Robot
Flagship product – SkyWalkerTM Orthopedic Surgical Robot Jun 2022 Dec 2022 FDA Clearance Won First Bid Apr 2022 Dec 2022 NMPA Approval CE Marking Indication expansion Integrated orthopaedic surgical robot platform compatible for both hip and knee Completed FIM Completed FIM for THA for UKA Collabora
Slide 15: Flagship product – DFVision 3D Electronic Laparoscope
Flagship product – DFVision® 3D Electronic Laparoscope Rapid commercialization – robust YoY Leading market share of new Upgraded system to further enrich the sales growth installation units among domestic 3D product portfolio brands in 2022 Stereo visualization The natural depth of field allows the
Slide 16: Natural Orifice Surgical Robot
Natural Orifice Surgical Robot Trans-bronchial Surgical Robot Robot-assisted natural orifice surgery Surgery application Product Natural orifice surgical robots refer to robots that deliver surgical instruments to the target anatomy through natural pathways of the human body and control them for d
Slide 17: R-ONE Vascular Interventional Surgical Robot
Presentation titl R-ONE ® Vascular Interventional Surgical Robot CE Marking Designed to operate with precision and perform specific movements Facilitate and enhance the interventional Features / Technology procedures performed on the patient Coronary angioplasty Indication application PCI live
Slide 18: Mona Lisa Robotic Transperineal Prostate Biopsy System
Mona Lisa Robotic Transperineal Prostate Biopsy System CE Marking Real-time 2D ultrasound images FDA approval displayed on the monitor during the biopsy procedure The surgeon manually inserts the needle Features / into the prostate to collect the biopsy Technology cores 1st unit of sales in Taiw
Slide 19: Strong industrial operation capabilities for surgical robots
Strong industrial operation capabilities for surgical robots 948 Multilayered supply chain system applications (844 invention patents) 304 Scalable production of Toumai®, SkyWalkerTM overseas applications (285 invention patents) Annual capacity over 100 units of system 445 Patents covering applicati
Slide 20: Outstanding award winning track record in 2022
Outstanding award winning track record in 2022 Apr Sept Dec Toumai® - China Hospital Development Program SkyWalkerTM - 2022 “Golden Ruyi” Award Germany iF Design Award Toumai® - SAIL Award at WAIC MedBot - Pioneer Enterprises in Digital Transformation of Biopharma Industry Mar Toumai® - 2022 reddot
Slide 21: Agenda
Agenda Business highlights Commercialization Product pipeline update Financial review Appendix CONFIDENTIAL 20
Slide 22: Core product breakthrough and adequately invested
Core product breakthrough and adequately invested Core-product Breakthrough Adequately Invested Free Cash-flow Management Total revenue reached 21.6m with 905% growth. Core On-going R&D projects were adequately invested and Operating cash-flow increased in line with the operating product Toumai® won
Slide 23: Investment on future – Operating Expenses
Investment on future – Operating Expenses Invest for future Prepare for sales ramp-up Support overall business growth R&D COST S&M EXPENSES ADMINISTRATIVE EXPENSES (RMB million) SBP (RMB million) SBP (RMB million) SBP 92% 184.0 170.5 755.8 59% 132% 18.1 89.9 28.9 190% 300% 107.5 392.6 2841% 79.2 22.
Slide 24: Research and Development Cost
Research and Development Cost FUND PIPELINE PRODUCTS INVEST IN FOUNDATION TECHNOLOGIES Others Others 16% 17% Orthopedic 755.8m Laparoscopic 755.8m Staff Costs 56% 51% 28% Costs of materials and consumables 32% Laparoscopic: Toumai®1st received NMPA approval in Jan 22; Staff Costs – R&D team to c
Slide 25: Agenda
Agenda Business highlights Commercialization Product pipeline update Financial review Appendix CONFIDENTIAL 24
Slide 26: Financial Statement – Balance Sheet
Financial Statement – Balance Sheet Unit: RMB'000 31 Dec 2022 31 Dec 2021 Var. Unit: RMB'000 31 Dec 2022 31 Dec 2021 Var. Non-current assets CAPITAL AND RESERVES Share capital 958,594 958,594 0% Property, plant and equipment 491,576 361,000 36% Intangible assets 7,053 3,074 129% Reserves 459,064 1,4
Slide 27: Financial Statement – P&L
Financial Statement – P&L Unit: RMB'000 2022 2021 Var. Revenue 21,603 2,150 905% Cost of sales (15,041) (1,231) 1122% Gross profit 6,562 919 614% Other net income 42,078 24,675 71% Selling and marketing expenses (184,042) (79,188) 132% Administrative expenses (170,472) (107,477) 59% Research and dev
Slide 28: Disclaimer
Disclaimer This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of Shanghai MicroPort MedBot (Group) Co., Ltd. (上海微创医疗机器人（集团） 股份有限公司) , and no p
Slide 29: Strictly Private and Confidential
Strictly Private and Confidential 28 CONFIDENTIAL
Shanghai MicroPort MedBot (Group) — FY2022 Earnings Presentation on 6ix